Faruqi & Faruqi, LLP reminds investors in Erasca, Inc. of the August 10, 2026 deadline to seek lead plaintiff appointment in a securities class action against the company. The lawsuit alleges that Erasca and its executives made false or misleading statements about preclinical data for its drug candidate ERAS-0015, which was based on improper comparisons to Revolution Medicines, Inc.'s proprietary compound, exposing Erasca to patent infringement and trade secret misappropriation claims. On April 27, 2026, Erasca disclosed a letter from RevMed's counsel alleging patent infringement and improper data comparisons, causing its stock to fall roughly 10.9 percent from a closing price of $21.49 on April 24 to $19.15 on April 27. Later that day, Erasca reported preliminary Phase 1 data revealing a patient death classified as a Grade 3 treatment-related adverse event and acknowledged that prior comparisons were not based on head-to-head clinical trials, sending shares down more than 45 percent to close at $9.90 on April 28. Investors who purchased Erasca securities between January 14, 2025 and April 26, 2026 and suffered losses may contact the firm to discuss their legal rights.
Erasca IncSecurities class action lawsuit alleging false statements about preclinical data and patent infringement, causing stock to drop over 45%.
Revolution Medicines IncErasca's improper comparison to Revolution Medicines' proprietary compound and subsequent patent infringement allegations highlight RevMed's competitive advantage.